Pathologic Function
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
uniQure, Huntington’s disease, AMT-130, gene therapy, Phase I/II trials, disease progression, neurofilament light protein (NfL), Unified Huntington’s Disease Rating Scale (cUHDRS), Regenerative Medicine Advanced Therapy (RMAT) designation
UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data
UniQure, Huntington’s disease, gene therapy, AMT-130, FDA, RMAT designation, Phase I/II clinical trials, neurodegenerative disorder, neurofilament light (NfL), disease progression, composite Unified Huntington’s Disease Rating Scale (cUHDRS).
Alumis Completes IPO, Raising $250 Million for Inflammation and Immunology Research
Alumis, IPO, Inflammation, Immunology, Biotech, TYK2 Inhibitor, Plaque Psoriasis, Uveitis, Lupus
Amber Therapeutics Raises $100M for Closed-Loop Neuromodulation Implant for Urinary Incontinence
Amber Therapeutics, urinary incontinence, neuromodulation, closed-loop implant, funding, series A round, pelvic pudendal nerve, mixed incontinence, U.S. regulatory approval.
Boehringer Ingelheim and Zealand Unveil Promising Fibrosis Data from Mid-Stage MASH Trial
Boehringer Ingelheim, Zealand, fibrosis, MASH trial, mid-stage, Phase II data, liver scarring, treatment
Lilly Touts Fibrosis Win, Strengthens Case for Tirzepatide in MASH Treatment
Eli Lilly, Tirzepatide, MASH, Fibrosis, Liver Disease, Obesity, Diabetes, GLP-1/GIP Dual Agonist
Amgen’s Uplizna Achieves Success in Phase 3 Trial for Immunoglobulin G4-Related Disease (IgG4-RD)
Amgen, Uplizna, IgG4-RD, Phase 3 Trial, Autoimmune Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD)
Lilly’s Tirzepatide Demonstrates Efficacy in Mid-Stage MASH Study
Tirzepatide, MASH, Eli Lilly, Fibrosis, Liver Disease, Diabetes, Obesity
RYBREVANT: A Breakthrough in Lung Cancer Treatment
RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)